MedTrace Logo

Impact of Ziwig Endotest® on the Management of Patients With Clinical Symptoms of Endometriosis Inconsistent With Their Imaging Work-up

NCT06794424 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2503

Last updated 2026-03-25

No results posted yet for this study

Summary

The goal of this study is to evaluate the impact of Ziiwg Endotest on patient management decisions before and after the test. The main questions it aims to answer are:

* Does the test reduce the intention and number of laparoscopies in women whose decision to undergo laparoscopy was made before the test result was obtained?
* Does the test change management decisions in women with no prior indication for diagnostic laparoscopy?

Study will compare the patient management decision before and after the test.

The acts and procedures performed as part of this research are :

* Aa saliva sampling (Ziwig Endotest) at inclusion
* A mutidisciplinary meeting post test (if applicable)
* Completion at inclusion and 6 month of a quality-of-life questionnaire (EHP-5)
* Completion at inclusion and 6 month of a VAS for pain
* Completion at inclusion and 6 month of a Likert satisfaction scale
* A test results Announcement consultation
* A visit at 6 months.

Conditions

  • Endometriosis

Interventions

DIAGNOSTIC_TEST

Ziwig Endotest®

Saliva sampling for Endometriosis diagnostic

Sponsors & Collaborators

  • Monitoring Force Group

    collaborator INDUSTRY

  • ZIWIG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-14
Primary Completion
2026-09-01
Completion
2026-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794424 on ClinicalTrials.gov